Skip to main content
. Author manuscript; available in PMC: 2019 Aug 26.
Published in final edited form as: Pharmacotherapy. 2015 Apr;35(4):412–423. doi: 10.1002/phar.1561

Figure 4:

Figure 4:

Clinical outcomes stratified by reason for tumor necrosis factor antagonist failure. Rates of clinical response, clinical remission, and mucosal healing at week 6 are shown in panel A; durable clinical response, durable clinical remission, and mucosal healing at week 52 are shown in panel B. VDZ = vedolizumab.